JP2024540183A5 - - Google Patents

Info

Publication number
JP2024540183A5
JP2024540183A5 JP2024525662A JP2024525662A JP2024540183A5 JP 2024540183 A5 JP2024540183 A5 JP 2024540183A5 JP 2024525662 A JP2024525662 A JP 2024525662A JP 2024525662 A JP2024525662 A JP 2024525662A JP 2024540183 A5 JP2024540183 A5 JP 2024540183A5
Authority
JP
Japan
Prior art keywords
preparation
prevention
treatment
compound
agents
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2024525662A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024540183A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/CN2022/129479 external-priority patent/WO2023078333A1/zh
Publication of JP2024540183A publication Critical patent/JP2024540183A/ja
Publication of JP2024540183A5 publication Critical patent/JP2024540183A5/ja
Pending legal-status Critical Current

Links

JP2024525662A 2021-11-03 2022-11-03 置換されたフェニルプロピオン酸誘導体及びその使用 Pending JP2024540183A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
CN202111293711.9 2021-11-03
CN202111293711 2021-11-03
CN202211033065 2022-08-26
CN202211033065.7 2022-08-26
PCT/CN2022/129479 WO2023078333A1 (zh) 2021-11-03 2022-11-03 一种取代的苯丙酸衍生物及其用途一种取代的苯丙酸衍生物及其用途

Publications (2)

Publication Number Publication Date
JP2024540183A JP2024540183A (ja) 2024-10-31
JP2024540183A5 true JP2024540183A5 (cg-RX-API-DMAC7.html) 2026-03-19

Family

ID=86240694

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2024525662A Pending JP2024540183A (ja) 2021-11-03 2022-11-03 置換されたフェニルプロピオン酸誘導体及びその使用

Country Status (10)

Country Link
US (1) US20250042847A1 (cg-RX-API-DMAC7.html)
EP (1) EP4428129A4 (cg-RX-API-DMAC7.html)
JP (1) JP2024540183A (cg-RX-API-DMAC7.html)
KR (1) KR20240091010A (cg-RX-API-DMAC7.html)
CN (1) CN118055927A (cg-RX-API-DMAC7.html)
AU (1) AU2022381258A1 (cg-RX-API-DMAC7.html)
CA (1) CA3235992A1 (cg-RX-API-DMAC7.html)
MX (1) MX2024005304A (cg-RX-API-DMAC7.html)
TW (1) TW202334116A (cg-RX-API-DMAC7.html)
WO (1) WO2023078333A1 (cg-RX-API-DMAC7.html)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2024217537A1 (zh) * 2023-04-21 2024-10-24 深圳信立泰药业股份有限公司 一种叔胺类化合物及其制备方法和医药用途
TW202444710A (zh) * 2023-05-11 2024-11-16 大陸商江蘇恆瑞醫藥股份有限公司 一種脂蛋白化合物晶型及其製備方法
KR20260041098A (ko) * 2023-07-21 2026-03-26 일라이 릴리 앤드 캄파니 Lp(a) 저하 활성을 갖는 피롤리딘 화합물
CN121548567A (zh) * 2023-07-21 2026-02-17 伊莱利利公司 具有Lp(a)降低活性的哌啶、吗啉和四氢哒嗪化合物
CN119490445A (zh) * 2023-08-15 2025-02-21 深圳信立泰药业股份有限公司 一种酰基类化合物及其制备方法和医药用途
CN122535600A (zh) * 2023-11-17 2026-08-07 上海翊石医药科技有限公司 一种取代的2-(吡咯烷-3-基)乙酸的衍生物及其制备方法和用途
CN122270439A (zh) * 2023-11-20 2026-06-23 上海齐鲁制药研究中心有限公司 一种多环类衍生物、其制备方法和应用
WO2025199298A1 (en) 2024-03-21 2025-09-25 Eli Lilly And Company BIOMARKER ASSAY TO MEASURE LIPOPROTEIN(a)
WO2025237188A1 (zh) * 2024-05-14 2025-11-20 石家庄以岭药业股份有限公司 一种LP(a)抑制剂化合物及其应用
CN121627662A (zh) * 2024-09-05 2026-03-10 成都康弘药业集团股份有限公司 芳基丙酸化合物及其制备方法与用途
WO2026061518A1 (zh) * 2024-09-23 2026-03-26 上海京新生物医药有限公司 一种环状胺衍生物的固体形式、制备方法及药物组合物
WO2026119122A1 (zh) * 2024-12-02 2026-06-11 上海喆邺生物科技有限公司 一种苯丙酸衍生物及其医药用途
WO2026130347A1 (zh) * 2024-12-17 2026-06-25 上海喆邺生物科技有限公司 一种吡咯烷衍生物及其在药物中的用途
WO2026130471A1 (zh) * 2024-12-18 2026-06-25 江苏恒瑞医药股份有限公司 吡咯烷衍生物或其盐的制备方法
CN121609698B (zh) * 2026-01-30 2026-06-02 山东京新药业有限公司 一种莫伐培林及中间体的制备方法

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1962596A (zh) * 2000-10-11 2007-05-16 埃斯佩里安医疗公司 用于控制胆固醇以及相关用途的酮化合物以及组合物
MXPA03003021A (es) * 2000-10-11 2003-07-14 Esperion Therapeutics Inc Compuestos de eter y composiciones para el control del colesterol y usos relacionados.
US7371777B2 (en) * 2001-08-17 2008-05-13 Eisai Co., Ltd. Cyclic compound and PPAR agonist
AU2003300438A1 (en) * 2003-12-24 2005-08-03 Esperion Therapeutics, Inc. Ether compounds and compositions for cholesterol management and related uses
US7705177B2 (en) * 2003-12-24 2010-04-27 Esperion Therapuetics, Inc. Ketone compounds and compositions for cholesterol management and related uses
US7919506B2 (en) * 2006-03-10 2011-04-05 Pfizer Inc. Dibenzyl amine compounds and derivatives
CA2708706A1 (en) * 2007-12-10 2009-06-18 7Tm Pharma A/S Cannabinoid receptor modulators
KR102720992B1 (ko) 2019-06-07 2024-10-24 일라이 릴리 앤드 캄파니 피롤리딘 화합물
EP4469435A1 (en) * 2022-01-26 2024-12-04 Eli Lilly and Company Pyrrolidine compounds

Similar Documents

Publication Publication Date Title
JP2021063088A5 (cg-RX-API-DMAC7.html)
JP2023002662A5 (cg-RX-API-DMAC7.html)
JP2015526458A5 (cg-RX-API-DMAC7.html)
JP2022191257A5 (cg-RX-API-DMAC7.html)
JP2010518122A5 (cg-RX-API-DMAC7.html)
JP2017528507A5 (cg-RX-API-DMAC7.html)
JP2004522714A5 (cg-RX-API-DMAC7.html)
JP2009535352A5 (cg-RX-API-DMAC7.html)
JP2019533660A5 (cg-RX-API-DMAC7.html)
RU2018136580A (ru) Цитратная соль (s)-4-((s)-3-фтор-3-(2-(5,6,7,8-тетрагидро-1,8-нафтиридин-2-ил)этил)пирролидин-1-ил)-3-(3-(2-метоксиэтокси)фенил)бутановой кислоты
EP4494701A3 (en) New therapeutic combinations for the treatment of progressive fibrosing interstitial lung diseases
JP2014139255A5 (cg-RX-API-DMAC7.html)
JP2021502392A5 (cg-RX-API-DMAC7.html)
JP2022533968A5 (cg-RX-API-DMAC7.html)
JP2023531675A5 (cg-RX-API-DMAC7.html)
JP2022551691A5 (cg-RX-API-DMAC7.html)
JP2005508963A5 (cg-RX-API-DMAC7.html)
JP2022531251A5 (cg-RX-API-DMAC7.html)
JP2024523559A5 (cg-RX-API-DMAC7.html)
JP5680412B2 (ja) レオヌリンの使用およびその組成物
JP2023531930A5 (cg-RX-API-DMAC7.html)
JP2023553253A5 (cg-RX-API-DMAC7.html)
JP2019507786A5 (cg-RX-API-DMAC7.html)
Goldschmidt et al. Compound cardiac toxicity of oral erythromycin and verapamil
JP2024523406A5 (cg-RX-API-DMAC7.html)